黄芪治疗糖尿病肾病的临床研究

Clinical Study on Treatment of Diabetic Nephropathy with Astragalus Membranaceus

目的研究黄芪对糖尿病肾病的临床治疗疗效。方法选取该院诊断为糖尿病肾病患者138例,将患者随机分为两组,对照组68例,年龄33~59岁,平均年龄为(40±2.1)岁,观察组70例,年龄30~60岁,平均年龄为(39±3.2)岁。其中对照组采用糖尿病肾病的常规治疗方法,观察组在常规治疗的基础上采用黄芪用药,比较两组患者在治疗后的血浆白蛋白,24 h尿蛋白定量以及治疗疗效。结果两组患者治疗后,观察组的总有效率(88.0%)要远远高于对照组(70.6%)。治疗后,观察组的血浆白蛋白为(1.72±0.02)g/L,要小于对照组的血浆白蛋白(3.32±0.32)g/L,观察组的24 h尿蛋白定量为(25.62±3.27)g,小于对照组的24 h尿蛋白定量(30.89±3.56)g,两组比较两个指标均差异有统计学意义(P<0.05)。结论黄芪治疗糖尿病肾病的疗效良好,可以应用于临床推广。

Objective To study the clinical curative effect of astragalus on diabetic nephropathy. Methods 138 patients with diabetic nephropathy were randomly divided into two groups： control group （ n=68）,age （33？59） years, mean age （40±2.1） years old, observation group 70 cases,30-60 years old, with an average age of （39±3.2） years. The control group was treated with conventional treatment of diabetic nephropathy. The observation group was treated with astragalus on the basis of routine treatment. The plasma albumin, 24h urinary protein and the therapeutic effect were compared between the two groups. Results The total effective rate（ 88%） in the observation group was significantly higher than that in the control group （70.6%） after treatment. After treatment, the plasma albumin was （1.72±0.02） g/L in the observation group, which was smaller than the plasma albumin （3.32±0.32）g/L in the control group. The 24h urine protein was （25.62±3.27） g （30.89±3.56） g in the control group, and the difference between the two groups was statistically significant（P 〈0.05）. Conclusion Astragalus treatment of diabetic nephropathy is effective and can be applied in clinical practice.